Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 months, according to a Genentech press release.
Vabysmo (faricimab-svoa) is a bispecific antibody that inhibits angiopoietin-1 and VEGF-A. It is also approved for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
It was approved for macular edema due to retinal vein occlusion (RVO) in 2023, and the label update allows patients to continue using it